Viome Life Sciences, Inc. launched the CancerDetect test for oral and throat cancer. Further, this test also fills a market gap by offering advanced, early detection at the point when it is most controllable and is the first to find biomarkers for early-stage oral and throat cancers.
Seres Therapeutics, Inc. teamed up with Bacthera to produce SER-109, for reoccurring Clostridium difficile infection (rCDI). Further, the collaboration enhanced the initial commercial manufacturing supply chain, which will strengthen SER-109's commercial production capacities and provide supply support.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4062
Published Date: May 02, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Growing prevalence of the human microbiome in health and disease and increasing research on its major impact on human physiology, metabolic and immune functions are the major factors driving the market growth.
The market size of the human microbiome is anticipated to attain a CAGR of 25% over the forecast period, i.e., 2023-2035.
The major players in the market are Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, Inc., Second Genome Inc., Synthetic Biologics, Inc., YSOPIA Bioscience, 4D pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc.
The probiotics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.